ONO PHARMACEUTICAL CO.,LTD.

May 7, 2018

Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma

NEWTON, Mass., April 30, 2018 -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, reported positive top-line results from the Phase 2b STORM study evaluating the Company's lead, oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor in heavily pretreated patients with refractory multiple myeloma. Regarding the STORM study's primary objective, oral selinexor achieved a 25.4% overall response rate (ORR), which included two complete responses (CRs) and 29 partial (PRs) or very good partial responses (VGPRs) in these patients with penta-refractory myeloma. The median duration of response (DOR), a key secondary objective, was 4.4 months. All responses were confirmed by an Independent Review Committee (IRC). Selinexor was recently granted Fast-Track designation by the U.S. Food and Drug Administration (FDA) for this indication.

In October 2017, Ono Pharmaceutical Co., Ltd. concluded an exclusive license agreement with Karyopharm Therapeutics Inc. for the development and commercialization of Selinexor, their first-in-class oral XPO1 (Exportin 1) inhibitor, and KPT-8602, a second-generation oral XPO1 inhibitor, for all oncology indications exclusively in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries.

Please click here for the press release distributed by Karyopharm.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp